|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||46.96 kg/mol|
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration. It binds to complement factor D (CFD).
Enrollment in Phase 3 clinical trials was initiated in 2014. Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
- Roche starts Phase III trials of lampalizumab, PharmaTimes
- What are clinical trial phases?, NIH - US National Library of Medicine.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|